The American Journal of Medicine
Volume 121, Issue 8, Supplement 2 , Pages S3-S10 , August 2008

Epidemiology of Benign Prostatic Hyperplasia and Comorbidities in Racial and Ethnic Minority Populations

  • Gerald P. Hoke, MD, MPH

      Affiliations

    • Department of Urology, New York-Presbyterian Medical Center, Department of Urology, Columbia University Medical College, New York, New York, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Gerald P. Hoke, MD, MPH, Department of Urology, New York-Presbyterian Medical Center, 180 Fort Washington Avenue, New York, NY 10032.
    • ,
  • Glen W. McWilliams, MD

      Affiliations

    • Department of Urology, Mount Sinai School of Medicine, New York, New York, USA

References 

  1. Platz EA, Smit E, Curhan GC, Nyberg LM, Giovannucci E. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in US men. Urology. 2002;59:877–883
  2. Da Silva FC. Benign prostatic hyperplasia: natural evolution versus medical treatment. Eur Urol. 1997;32(suppl 2):34–37
  3. Roehrborn CG, Marks L, Harkaway R. Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners. Prostate Cancer Prostatic Dis. 2006;9:30–34
  4. Collins MF, Friedman RH, Ash A, Hall R, Moskowitz MA. Underdetection of clinical benign prostatic hyperplasia in a general medical practice. J Gen Intern Med. 1996;11:513–518
  5. Naslund MJ, Gilsenan AW, Midkiff KD, Bown A, Wolford ET, Wang J. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int J Clin Pract. 2007;61:1437–1445
  6. Wong SY, Hong A, Leung J, Kwok T, Leung PC, Woo J. Lower urinary tract symptoms and depressive symptoms in elderly men. J Affect Disord. 2006;96:83–88
  7. Kuritzky L. Role of primary care clinicians in the diagnosis and treatment of LUTS and BPH. Rev Urol. 2004;6(suppl 9):S53–S59
  8. Saigal CS, Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol. 2005;173:1309–1313
  9. Census bureau projects tripling of Hispanic and Asian populations in 50 years; non-hispanic whites may drop to half of total population [press release]. Washington DC: US Census Bureau News, US Dept of Commerce; March 18, 2004. http://www.census.gov/Press-Release/www/releases/archives/population/001720.htmlAccessed November 30, 2006
  10. Naslund MJ, Issa MM, Grogg AL, Eaddy MT, Black L. Clinical and economic outcomes in patients treated for enlarged prostate. Am J Manag Care. 2006;12(suppl):S111–S116
  11. Platz EA, Kawachi I, Rimm EB, Willet WC, Giovannuci E. Race, ethnicity and benign prostatic hyperplasia in the Health Professionals Follow-up Study. J Urol. 2000;163:490–495
  12. Wei JT, Schottenfeld D, Cooper K, et al. The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol. 2001;165:1521–1525
  13. Sarma A, McLaughlin JC, Jacobsen SJ, et al. Longitudinal changes in lower urinary tract symptoms among a cohort of black American men: the Flint Men's Health Study. Urology. 2004;64:959–965
  14. Lee AJ, Garraway WM, Simpson RJ, Fisher W, King D. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur Urol. 1998;34:325–332
  15. Joseph MA, Harlow SD, Wei JT, et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol. 2003;157:906–914
  16. Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer. 1988;57:216–218
  17. McConnell JD. The pathophysiology of benign prostatic hyperplasia. J Androl. 1991;12:356–363
  18. Ingles SA, Ross RK, Yu MC, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst. 1997;89:166–170
  19. Giovannucci E, Platz EA, Stampfer MJ, et al. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology. 1999;53:121–125
  20. Mitsumori K, Terai A, Oka H, et al. Androgen receptor CAG repeat length polymorphism in benign prostatic hyperplasia (BPH): correlation with adenoma growth. Prostate. 1999;41:253–257
  21. Nelson KA, Witte JS. Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol. 2002;155:883–890
  22. Pettaway CA. Racial differences in the androgen/androgen receptor pathway in prostate cancer. J Natl Med Assoc. 1999;91:653–660
  23. Wu AH, Whittemore AS, Kolonel LN, et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev. 1995;4:735–741
  24. McNeal J. Pathology of benign prostatic hyperplasia: insight into etiology. Urol Clin North Am. 1990;17:477–486
  25. Aoki Y, Arai Y, Maeda H, Okubo K, Shinohara K. Racial differences in cellular composition of benign prostatic hyperplasia. Prostate. 2001;49:243–250
  26. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003) (Chapter 1: diagnosis and treatment recommendations). J Urol. 2003;170:530–547
  27. Gonzalez RR, Kaplan SA. First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?. World J Urol. 2006;24:360–366
  28. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47:824–837
  29. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol. 2003;44:637–649
  30. Gomery P, Bullock A, McGettigan J, et al. Tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction: results from multiple observations in men with erectile dysfunction in national tadalafil study in the US (MOMENTUS). [published correction appears in Int J Impot Res. 2007;19:339] Int J Impot Res. 2007;19:76–83
  31. Enger SM, Van Den Eeden SK, Sternfeld B, et al. California Men's Health Study (CMHS): a multiethnic cohort in a managed care setting. BMC Public Health. 2006;6:172–180
  32. Ganz P. Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease. Am J Cardiol. 2005;96:8M–12M
  33. Billups KL, Bank AJ, Padma-Nathan H, Katz S, Williams R. Erectile dysfunction is a marker for cardiovascular disease: results of the minority health institute expert advisory panel. J Sex Med. 2005;2:40–50
  34. Barqawi A, O'Donnell C, Kumar R, Koul H, Crawford ED. Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse male population: data from the Prostate Cancer Awareness Week (PCAW). Int J Impot Res. 2005;17:370–374
  35. Kramer H, Han C, Post W, et al. Racial/ethnic differences in hypertension and hypertension treatment and control in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens. 2004;17:963–970
  36. Wong MD, Shapiro MF, Boscardin WJ, Ettner SL. Contribution of major diseases to disparities in mortality. N Engl J Med. 2002;347:1585–1592
  37. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol. 2004;172:1390–1393
  38. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl. 1995;168:7–12
  39. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999;8:29–36
  40. American Heart Association. Statistical fact sheet—populations: African Americans and cardiovascular diseases [AHA Web site]. http://www.americanheart.org/downloadable/heart/1136405578457AfrAmerican06.pdfAccessed November 30, 2006
  41. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Examination Survey. JAMA. 2002;287:356–359
  42. Berger AP, Bartsch G, Deibl M, et al. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int. 2006;98:1038–1042
  43. Weisman KM, Larijani GE, Goldstein MR, Goldberg ME. Relationship between benign prostatic hyperplasia and history of coronary artery disease in elderly men. Pharmacotherapy. 2000;20:383–386
  44. American Diabetes Association. Total Prevalence of Diabetes & Pre-diabetes [American Diabetes Association Web site]. http://www.diabetes.org/diabetes-statistics/prevalence.jspAccessed November 29, 2006
  45. National Institutes of Health. National Institutes of Health Type 2 Diabetes Fact Sheet [NIH Web site]. http://www.nih.gov/about/researchresultsforthepublic/Type2Diabetes.pdfAccessed December 5, 2006
  46. Skelly AH. Type 2 diabetes mellitus. Nurs Clin North Am. 2006;41:531–547, vi
  47. Glynn RJ, Campion EW, Bouchard GR, Silbert JE. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol. 1985;121:78–90
  48. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol. 2000;163:1725–1729
  49. Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:2562–2568
  50. Michel MC, Mehlburger L, Bressel HU, Schumacher H, Schäpers RF, Goepel M. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability?. J Urol. 1998;160:784–791
  51. Berger AP, Deibl M, Leonhartsberger N, et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int. 2005;96:1073–1078
  52. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  53. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2003;163:427–436
  54. Hall WD, Clark LT, Wenger NK, et al. The metabolic syndrome in African Americans: a review. Ethn Dis. 2003;13:414–428
  55. Hammarsten J, Hogstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press. 2004;13:47–55
  56. Kasturi S, Russell S, McVary KT. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep. 2006;7:288–292
  57. McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2005;174:1327–1433
  58. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond). 2005;29:310–316
  59. Rohrmann S, DeMarzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate. 2005;62:27–33
  60. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. In:  Smedley BD,  Stith AY,  Nelson AR editor. Washington, DC: National Academies Press; 2002;

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)00507-X

doi: 10.1016/j.amjmed.2008.05.021

The American Journal of Medicine
Volume 121, Issue 8, Supplement 2 , Pages S3-S10 , August 2008

Article Tools

* Image Usage & Resolution